These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 23764841)

  • 1. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
    Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
    Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
    Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
    Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
    Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
    [No Abstract]   [Full Text] [Related]  

  • 6. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
    Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
    Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
    Koelsche C; Sahm F; Capper D; Reuss D; Sturm D; Jones DT; Kool M; Northcott PA; Wiestler B; Böhmer K; Meyer J; Mawrin C; Hartmann C; Mittelbronn M; Platten M; Brokinkel B; Seiz M; Herold-Mende C; Unterberg A; Schittenhelm J; Weller M; Pfister S; Wick W; Korshunov A; von Deimling A
    Acta Neuropathol; 2013 Dec; 126(6):907-15. PubMed ID: 24154961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
    Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
    Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphous oligodendroglioma of Zülch revisited: a genetically heterogeneous group of anaplastic gliomas including tumors of bona fide oligodendroglial differentiation.
    Hewer E; Beck J; Murek M; Kappeler A; Vassella E; Vajtai I
    Neuropathology; 2014 Aug; 34(4):323-32. PubMed ID: 24444336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.
    You H; Wu Y; Chang K; Shi X; Chen XD; Yan W; Li R
    CNS Neurosci Ther; 2017 Oct; 23(10):790-797. PubMed ID: 28868656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.
    Terzi NK; Yilmaz I; Oz AB
    Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
    Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
    Zhang Z; Chan AK; Ding X; Li Y; Zhang R; Chen L; Liu Y; Wang Y; Xiong J; Ng HK; Yao Y; Zhou L
    Neuro Oncol; 2017 Jul; 19(7):1008-1010. PubMed ID: 28874004
    [No Abstract]   [Full Text] [Related]  

  • 20. Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
    Masui K; Komori T; Kato Y; Masutomi K; Ichimura K; Ogasawara S; Kaneko MK; Oki H; Suzuki H; Nitta M; Maruyama T; Muragaki Y; Kawamata T; Sawada T; Shibata N
    Biomed Res Int; 2018; 2018():7945845. PubMed ID: 29693015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.